David founded Oncora during his training in the Medical Scientist Training Program at the University of Pennsylvania, where he received his PhD in engineering for his work developing and applying machine learning technology to diagnose lung cancer. With Oncora, he has built and deployed research-grade and commercial machine learning solutions for physicians at leading institutions across the US. David brings a combination of clinical knowledge and experience in regulatory affairs, clinical trial design, and reimbursement strategy to the Oncora leadership team. As Oncora’s CEO since founding in 2014, David has developed close relationships with clinical and business leaders in the oncology space and leads partnerships, sales, and investor relations. He is also an active contributor to Oncora’s product, data science, and engineering teams. In addition to serving as Oncora's CEO, David is a medical student, finishing his final year at the University of Pennsylvania.
Chris is a computer scientist and machine learning expert with a PhD from Georgia Tech and BS from Caltech. Chris has nine years of academic and industry research experience and has worked with field-leading experts in both DNA computing and theoretical machine learning. His graduate research, resulting in several publications in top machine learning conferences, focused on theoretically sound algorithms for active learning and on demonstrating that active learning can be used to overcome a variety of obstacles in machine learning. At Oncora, Chris leads product development and research.
Gary has 25+ years of experience in operations and investments. He joined Safeguard Scientifics in 2006 where he is responsible for identifying, deploying capital in and supporting emerging healthcare companies in diagnostics, medical devices and healthcare IT. Gary is currently a board member of Good Start Genetics, Medivo, meQuilibrium, Propeller Health, Syapse and Trice Medical and is a board observer at Velano Vascular. He recently realized successful exits with partner companies Advanced BioHealing, Alverix, Avid Radiopharmaceuticals, Crescendo Biosciences and NuPathe to strategic acquirers Shire, Becton Dickinson, Eli Lilly, Myriad, and Teva, respectively. Previously, he was Chief Executive Officer at Pluvita Corporation, a company developing personalized medicine solutions and served as Chief Operating Officer at Genovo, and head of research & development at Avigen, both development stage gene therapy companies. Gary began his career in industry with Gilead Sciences as virology group leader. Gary received his MD degree from Washington University, trained in internal medicine at Barnes Hospital in St. Louis, MO, and completed hematology sub-specialty training at Stanford.
Jeff Simon is the CEO of Sun Nuclear Corporation where he leads company strategy with responsibility and accountability for all aspects of the business. Jeff is an expert in oncology software sales and marketing as well as a proven corporate leader driving innovation and growth. Jeff serves as a special advisor to Oncora's CEO on topics ranging from sales and marketing to strategic planning, operations, and leadership. Jeff is also a major investor in Oncora and serves as an observer to the board of directors.
Dr. Aaron Kamauu (MD, MS Biomedical Informatics, MPH, University of Utah School of Medicine) is an industry-leading advisor in the Real-World Data (RWD) space, specifically focusing on leveraging real-world healthcare data to support a variety of clinical research, informatics, clinical trials, and drug development activities, including pharmacoepidemiology, outcomes research, protocol design, site identification, data-driven patient recruitment, and the use of RWD to support evidence generation & submission to regulatory agencies (e.g., FDA). He has this experience across the spectrum of pharmaceutical/biotech, entrepreneurship, and large CRO businesses.